Because the CaMKII-dependent SR Ca leak may increase the risk of AF in patients with SDB, it may represent a potential pharmaceutical target for the prevention or treatment of AF, especially since clinical CaMKII inhibitors are currently under development. The gene discussed is CAMK2G; the disease is atrial fibrillation.